- Conditions
- Postural Tachycardia Syndrome, Autonomic Dysfunction, Postural Orthostatic Tachycardia Syndrome, POTS - Postural Orthostatic Tachycardia Syndrome
- Interventions
- GammaCore intervention, STEPS management protocol
- Device · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 12 Years to 19 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 2,866
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Ventricular Septal Defect
- Interventions
- saline, ketamine
- Drug
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- Up to 1 Year
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Dry Eye Disease
- Interventions
- NOV03, Saline Solution
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 35
- States / cities
- Phoenix, Arizona • Garden Grove, California • Hemet, California + 29 more
- Conditions
- Inflammation
- Interventions
- aldosterone, low or high sodium diet, placebo
- Drug · Dietary Supplement
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Advanced Solid Tumor
- Interventions
- PM14
- Drug
- Lead sponsor
- PharmaMar
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2025
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Houston, Texas
- Conditions
- Autoimmune Disorders
- Interventions
- Ublituximab, Placebo for Ublituximab
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Brain Injuries
- Interventions
- NNZ-2566, Placebo
- Drug
- Lead sponsor
- Neuren Pharmaceuticals Limited
- Industry
- Eligibility
- 16 Years to 75 Years
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 6
- States / cities
- Colton, California • Sacramento, California • Honolulu, Hawaii + 2 more
- Conditions
- Hyperopia, Myopia
- Interventions
- 1% EXP039, Saline control
- Drug · Other
- Lead sponsor
- Canyon City Eyecare
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Azusa, California
- Conditions
- Knee Replacement
- Interventions
- Aquamantys, Tourniquet
- Device
- Lead sponsor
- Stephen Duncan
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 73 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Lexington, Kentucky
- Conditions
- Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, External Beam Radiation Therapy, Paclitaxel, Positron Emission Tomography, Questionnaire Administration
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Dengue Fever
- Interventions
- Takeda's Dengue Tetravalent Vaccine (Live, Attenuated) (TDV), Placebo
- Biological
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 13 Years to 63 Years
- Enrollment
- 365 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 8
- States / cities
- Huntsville, Alabama • Peoria, Illinois • Newton, Kansas + 5 more
- Conditions
- Skin Diseases, Infectious
- Interventions
- Daptomycin, Standard of Care (SOC)
- Drug
- Lead sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Oakland, California • Orange, California + 18 more
- Conditions
- Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Carboplatin, Cisplatin, Cyclophosphamide, Etoposide, Filgrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Methotrexate, Quality-of-Life Assessment, Thiotepa, Vincristine Sulfate
- Procedure · Drug · Biological + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 2 Years
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2025
- U.S. locations
- 129
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 100 more
- Conditions
- Healthy Subjects
- Interventions
- Ketamine, Nicotine, Placebo, Ketamine and Nicotine
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2009
- U.S. locations
- 1
- States / cities
- West Haven, Connecticut
- Conditions
- Cataracts
- Interventions
- Viscoat, Saline
- Drug
- Lead sponsor
- Innovative Medical
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Boynton Beach, Florida • Maitland, Florida
- Conditions
- PTSD, Alcohol Use Disorder
- Interventions
- 40 IU Intranasal Oxytocin, Placebo, Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
- Drug · Behavioral
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Healthy Adult
- Interventions
- L-histidine, Monosodium glutamate (MSG), Sodium chloride (NaCl)
- Dietary Supplement
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8
- Interventions
- Biopsy Procedure, Biospecimen Collection, Chest Radiography, Cisplatin, Computed Tomography, Echocardiography Test, Electronic Health Record Review, Fluciclovine F18, Gemcitabine, Magnetic Resonance Imaging, Multigated Acquisition Scan, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, X-Ray Imaging
- Procedure · Drug · Other + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 67 more
- Conditions
- Gulf War Illness
- Interventions
- plain crystalline niacin, exercise, sauna
- Drug
- Lead sponsor
- University at Albany
- Other
- Eligibility
- Not listed
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- Annapolis, Maryland
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IVB Cervical Cancer American Joint Committee on Cancer (AJCC) v8
- Interventions
- Bevacizumab, Biospecimen Collection, Brachytherapy, Cisplatin, External Beam Radiation Therapy, Paclitaxel, Pembrolizumab, Questionnaire Administration
- Biological · Procedure · Radiation + 2 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Diego, California • Oklahoma City, Oklahoma + 1 more
- Conditions
- HIV Infections
- Interventions
- AIDSVAX B/E Vaccine, DNA-HIV-PT123 Vaccine, Placebo for DNA-HIV-PT123, Placebo for AIDSVAX B/E
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- San Francisco, California • New York, New York • Rochester, New York + 3 more
- Conditions
- Hypertension
- Interventions
- Saline, QCZ484
- Other · Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 396 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 64
- States / cities
- Andalusia, Alabama • Huntsville, Alabama • Saraland, Alabama + 59 more
- Conditions
- Stage IIIA Non-Small Cell Lung Cancer
- Interventions
- Cisplatin, Computed Tomography, Docetaxel, Fludeoxyglucose F-18, Gemcitabine Hydrochloride, Pemetrexed Disodium, Positron Emission Tomography
- Drug · Procedure · Radiation
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Postoperative Inflammatory Response
- Interventions
- Hydrocortisone, Saline
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York